Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 11/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | AR | P10275 | 2/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL6932400 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL6370134 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL10261067 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL13046615 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL15114813 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL24900238 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL13202859 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL5699764 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL10292969 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL19465688 | 1.00 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270786-A1 | STEROID COMPOUNDS | EPIRIUM BIO INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-12030986-B2 | Sustained release composition using biobased biodegradable hyperbranched polyesters | CENTRAL MICHIGAN UNIVERSITY (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030986-B2 | Sustained release composition using biobased biodegradable hyperbranched polyesters | CENTRAL MICHIGAN UNIVERSITY (US) | 2024-07-09 | — | — | US | disclosed |
| EP-3464598-B1 | APTAMER-BASED ANALYTE ASSAYS | UNIV COLUMBIA (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023288123-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF 3.ALPHA.,7.ALPHA.,11.BETA.-TRIHYDROXY-6.ALPHA.-ETHYL-5.BETA.-CHOLAN-24-OIC ACID | INTERECEPT PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11542298-B2 | Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof | EPIRIUM BIO INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220136029-A1 | BIOTECHNOLOGICAL OPTIMIZATION OF MICROORGANISMS FOR THE 1,2-DEHYDROGENATION OF STEROIDS | SANOFI (FR) | 2022-05-05 | — | — | US | disclosed |
| US-11026955-B2 | Synthetic bile acid compositions and methods | ALLERGAN SALES, LLC (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3795578-A2 | HYDROXYSTEROID COMPOUNDS, THEIR INTERMEDIATES, PROCESS OF PREPARATION, COMPOSITION AND USES THEREOF | Sphaera Pharma Pvt. Ltd. (IN) | 2021-03-24 | — | — | EP | disclosed |
| US-10954265-B2 | Structures and mechanism for the design of highly potent glucocorticoids | VAN ANDEL RESEARCH INSTITUTE (US) | 2021-03-23 | — | — | US | disclosed |
| US-20080146532-A1 | Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance | BIOVIE INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080004246-A1 | Transporter enhanced corticosteroid activity | BODOR LABORATORIES, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004246-A1 | Transporter enhanced corticosteroid activity | BODOR LABORATORIES, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007142842-A2 | COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | BODOR NICHOLAS S (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070249571-A1 | Novel conjugate compounds and dermatological compositions thereof | TAMARKIN PHARMACEUTICALS (IL) | 2007-10-25 | — | — | US | disclosed |
| US-20070249571-A1 | Novel conjugate compounds and dermatological compositions thereof | TAMARKIN PHARMACEUTICALS (IL) | 2007-10-25 | — | — | US | disclosed |
| US-20070142342-A1 | Pharmaceutical compounds | NICOX S.A. | 2007-06-21 | — | — | US | disclosed |
| US-20070142342-A1 | Pharmaceutical compounds | NICOX S.A. | 2007-06-21 | — | — | US | disclosed |
| US-7186708-B2 | Steroidal compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | disclosed |
| US-7186708-B2 | Steroidal compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142342-A1 | Pharmaceutical compounds | CYP11B2, CYP11B1, CYP2S1 | NR3C1 67/4885HIF1A 2241/4885HSD17B10 126/4885 |
| US-11542298-B2 | Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof | HSD17B7, HSD11B1, HSD3B1 | NR3C1 69/4885HIF1A 1620/4885HSD17B10 36/4885 |
| US-20080004246-A1 | Transporter enhanced corticosteroid activity | HSD3B1, HSD11B1, EBP | NR3C1 5/4885HIF1A 1372/4885HSD17B10 180/4885 |
| US-20240270786-A1 | STEROID COMPOUNDS | NR5A1, NR3C2, CYP17A1 | NR3C1 19/4885HIF1A 4641/4885HSD17B10 66/4885 |
| US-20080146532-A1 | Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance | HSD17B1, HSD17B11, HSD3B2 | NR3C1 79/4885HIF1A 483/4885HSD17B10 42/4885 |
| US-20070249571-A1 | Novel conjugate compounds and dermatological compositions thereof | CYP24A1, VDR, CYP2R1 | NR3C1 114/4885HIF1A 3550/4885HSD17B10 37/4885 |
| US-10954265-B2 | Structures and mechanism for the design of highly potent glucocorticoids | NR3C1, NR3C2, MC2R | NR3C1 1/4885HIF1A 4696/4885HSD17B10 204/4885 |
| US-12030986-B2 | Sustained release composition using biobased biodegradable hyperbranched polyesters | APEH, LCT, IDE | NR3C1 3390/4885HIF1A 2270/4885HSD17B10 49/4885 |
| US-11026955-B2 | Synthetic bile acid compositions and methods | NR1H4, CYP27A1, CYP7A1 | NR3C1 735/4885HIF1A 4334/4885HSD17B10 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.